Genetically Obese Mice Had Massively Altered Opioid Receptors and Peptides
Obese mice had 2.7× more kappa receptors, 2.3× more mu receptors, and dramatically elevated brain opioid peptide levels — suggesting a fundamentally rewired opioid system.
Quick Facts
What This Study Found
Genetically obese mice showed massive increases in opioid peptide levels and shifts in receptor types, with kappa receptors up 2.7-fold and mu receptors down 40%.
Key Numbers
How They Did This
Brain membrane binding assays measured mu, delta, and kappa receptor levels using specific radioligands. Opioid peptide levels were quantified by radioimmunoassay in brain and pituitary tissue.
Why This Research Matters
These striking opioid differences in obese mice suggest the opioid system plays a major role in overeating. The changes could drive excessive food intake and contribute to metabolic problems like high blood sugar and insulin resistance.
The Bigger Picture
Obesity may involve a fundamentally altered opioid system — not just more eating, but a different brain chemistry. This reframes obesity as a neurochemical disorder and opens opioid-targeted treatment approaches.
What This Study Doesn't Tell Us
This was an animal study using genetically obese mice (ob/ob), which lack the hormone leptin. Human obesity is much more complex and usually involves multiple genetic and environmental factors.
Questions This Raises
- ?Would opioid receptor blockers reduce obesity-driven eating?
- ?Are similar opioid changes present in human obesity?
Trust & Context
- Key Stat:
- 2.7-fold kappa receptor increase In genetically obese mouse brains — with matching peptide level elevations
- Evidence Grade:
- Preliminary animal study in one genetic obesity model — clear effects but limited to ob/ob mice.
- Study Age:
- Published in 1989 — established the opioid system alterations in genetic obesity.
- Original Title:
- Central mu, delta, and kappa opioid binding sites, and brain and pituitary beta-endorphin and met-enkephalin in genetically obese (ob/ob) and lean mice.
- Published In:
- Life sciences, 44(16), 1097-105 (1989)
- Authors:
- Khawaja, X Z(2), Bailey, C J, Green, I C(2)
- Database ID:
- RPEP-00120
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why do obese mice have more opioid receptors?
The opioid system drives food reward and motivation to eat. More receptors and peptides amplify these signals, creating a stronger drive to consume food.
Could blocking opioid receptors treat obesity?
Yes — the combination naltrexone/bupropion (Contrave) is an approved obesity medication that works partly by blocking the overactive opioid reward system.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00120APA
Khawaja, X Z; Bailey, C J; Green, I C. (1989). Central mu, delta, and kappa opioid binding sites, and brain and pituitary beta-endorphin and met-enkephalin in genetically obese (ob/ob) and lean mice.. Life sciences, 44(16), 1097-105.
MLA
Khawaja, X Z, et al. "Central mu, delta, and kappa opioid binding sites, and brain and pituitary beta-endorphin and met-enkephalin in genetically obese (ob/ob) and lean mice.." Life sciences, 1989.
RethinkPeptides
RethinkPeptides Research Database. "Central mu, delta, and kappa opioid binding sites, and brain..." RPEP-00120. Retrieved from https://rethinkpeptides.com/research/khawaja-1989-central-mu-delta-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.